Loading in 2 Seconds...
Loading in 2 Seconds...
PRESENTATION STRATEGIC MANAGEMENT AT RANBAXY LABORATORIES Ltd GROUP:-”12”. Prepared By: Ragini Patel Roll No.34 Rakesh Patel Roll No.35 Rimple Patel Roll No.36. RANBAXY LABORATRIES. Type : Public Founded : 1961
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Ragini Patel Roll No.34
Rakesh Patel Roll No.35
Rimple Patel Roll No.36
Type : Public
Founded : 1961
Headquarters : Gurgaon, Haryana, India
Key People : Tejandra Khanna, Chairman
Brian Tempest, Vice Chairman
Malvinder Singh, CEO
Industry : Pharmaceutical
Total revenue : Rs. 5,188 crore
Global revenue : Rs. 3,819 crore
Market cap : Rs. 15,077 crore
where it is present
Countries where it has : 8
Revenue targeted by : Rs. 9,400 crore ($ 2 billion)
Revenue targeted by : Rs. 23,520 crore ($ 5 billion)
Employees : 1100 in R&D
Website : www.ranbaxy.com
Mr. Tejandra Khanna Chairman
Brian.W. Tempest Vice Chairman
Mr. Malvinder Mohan Singh CEO & MD
Mr. Atul Sobti President
Dr. P.S Joshi Director
Ramesh L. Adige Executive Director
ANTI – INFECTION
G.I & NUTRITIONALS
CVS & DIABETES
NS AID & RELATED
“To become research based International pharmaceutical company.”
Achieving customer satisfaction is fundamental to our business.
Provide products & services of highest quality.
Practice dignity and euity in relationship and provide opportunities to our people to realise their full potential.
Ensure profitable Growth and enhance wealth of the shareholders.
Fosters mutually beneficial relations with all our business partners.
Manage our operations with high concern for safety and environment.
Be a responsible corporate citizen
“Achieve significance business in proprietary prescription products by 2012 with a strong presence in developed markets.”
Ranbaxy is focused on increasing the momentum in the generics business in its key markets through organic and inorganic growth routes. Growth is well spread across geographies with focus on emerging markets The Company continues to evaluate acquisition opportunities in India, emerging and developed markets to strengthen its business and competitiveness. Ranbaxy has forayed into high growth potential segments like Biologics, Oncology and injectables. These new growth areas will add significant depth to the existing product pipeline.
The Globalization Strategy
Poised For Growth
API Development And Production
Dosage Form Development And Manufacturing
Ranbaxy can provide Active Pharmaceutical Ingredients (API) for companies that want to manufacture their own product or brand without incurring the time and costs associated with developing the API, eliminating this step from the overall manufacturing process. Key advantages of using Ranbaxy's vertically integrated system are:
Continuity of supply,Consistent quality of product ,Competitive costs,Flexibility and resources to respond to changing market dynamics
Dosage Form Development and Manufacturing
Ranbaxy's experience as a global manufacturer makes it an ideal partner to take on the complex process of solid or liquid dosage form development. Ranbaxy continually uses reverse engineering to improve upon its development and manufacturing processes and enhance yield, with a focus on achieving greater cost efficiencies.
To expand product lines with minimum investment, Ranbaxy provides turnkey manufacturing services, including API and dosage form development, to allow companies to focus on marketing and selling the product. This is an efficient way to diversify product lines and increase profit margins, taking advantage of Ranbaxy's manufacturing capabilities and expertise.
Marketing Strategies is the department focused primarily on developing and executing strategies for the promotion and distribution of branded, generic and OTC products for RPI.
One of the key tasks for the department is to identify opportunities in different markets and distribution channels and pursue those to developing and establish new relationships in the marketplace. Managed Care and Internet marketing are a couple of key areas that the department is looking to introduce into its ever-expanding service offerings.
Model of Competition
Rivalry Among Competing Firms in Industry
Threat of New Entrants
Threat of New Entrants
Bargaining Power of Suppliers
Bargaining Power of Buyers
Threat of Substitute Products
Pharmaceuticals Industry is one of the most competitive industrys in the country with as many as 10,000 different players fighting for the same price.The top players in the country has only 6% market share and top 5 players together has about 18% market share.
Competitors of Ranbaxy in India are:-
Entry barriers in pharma industry is low.
Ranbaxy depends on certain organic chemicals .The chemical industry is again very competitive and fragmented.The chemicals used in the pharma industry are largely a commodity.The suppliers have very low bargaining power and the Ranbaxy can easily switch from their suppliers without incurring a very high cost.
In Ranbaxy or in any Pharma industries the buyers are scattered and they as such does not yeild power in the pricing of the products.However government with it’s policies,plays an important role in regulating pricing through the NPPA(National Pharmaceuticals Pricing Authority).
Pharmaceutical Industry is one of the most easily accessible industries for an entrepreneur in India.The capital requirement for an industries is very low so creating a regional distribution network is easy since the point of sales is restricted in this Industries in India.However creating the brandawareness franchisee amongst the doctor is the key for the long term survival.Also quality regulations by government may put some hindrance for establishing new manufacturing operations.
In recent times the advances made in the field of Bio-technology can prove to be a threat to synthetic pharmaceutical industries.